All In Biotech

Drug Trial Radar · NCT02249663

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Site Study to Evaluate the Therapeutic Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray, to Dymista™ Nasal Spray

Last checked: Nov 19, 2026Latest source record: Sep 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,535 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,535

Planned (sponsor's estimate)

Start

Aug 2014

Primary completion

Feb 2015

Sponsor

Lead sponsor
Teva Pharmaceuticals USATeva (TEVA)
Sponsor type
Industry
First posted
Sep 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the therapeutic equivalence of a test formulation of Azelastine hydrochloride and Fluticasone propionate Nasal Spray to the reference listed drug, Dymista™ Nasal Spray in the relief of the signs and symptoms of Seasonal Allergic Rhinitis.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • Azelastine hydrochloride and Fluticasone propionateDrug

    137/50 mcg Nasal Spray

  • Dymista™Drug

    137/50 mcg Nasal Spray

  • PlaceboOther

    Nasal spray with no pharmaceutically active content

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in average AM/PM reflective Total Nasal Symptom Score (rTNSS).Time frame: Days 1 to 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novum Pharmaceutical Research Services

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.